World First Korea Darbepoetin Biosimilar Approval To Speed CKD's Global Entry?

With a global first marketing authorization for its darbepoetin biosimilar in South Korea, Chong Kun Dang aims to speed up the product’s entry into the Japanese and other international markets and progress clinical rials with other biosimilars and novel biologics.